Impact of generic competition on market share and prices of cardiovascular medicines on the Bulgarian pharmaceutical market

Journal of Public Health

Volumn 19, Issue 1, 2011, Pages 91-100

  Manova, Manoela M ^a   Stoimenova, Assena ^a   Clerfeuille, Fabrice ^b   Petrova, Guenka I ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Competitors; Generics; Market share; Pharmaceutical market; Prices

Indexed keywords

BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SARTAN DERIVATIVE; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ARTICLE; DRUG MANUFACTURE; DRUG MARKETING; DRUG PACKAGING; PHARMACEUTICAL CARE; PHYSICIAN;

EID: 79551515417     PISSN: 09431853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10389-010-0352-8     Document Type: Article

References (27)

1. M Adriaen K De Witte S Simoens 2008 Pricing strategies of originator and generic medicines following patent expiry in Belgium J Generic Med 5 175 187 10.1057/jgm.2008.8 10.1057/jgm.2008.8 (Pubitemid 351560179)
2. I Al-Abbadi, et al. 2009 One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan Clin Ther 6 31 1335 1343 10.1016/j.clinthera.2009.05.021 10.1016/j.clinthera.2009.05.021
3. Dirach J (2000) New safe medicines faster: a new concept for drug development. EUFEPS report SE-175 72, pp 1-5. http://newmedfaster.com/ Attachments/New%20Safe%20Medicines%20Faster-Backgrounder-v3.pdf. Cited May 2010
4. Frye JE (2007) International drug price indicator guide. MSH, Cambridge, MA, USA
5. F Fyhrquist O Saijonmaa 2008 Renin-angiotensin system revisited J Intern Med 264 3 224 236 10.1111/j.1365-2796.2008.01981.x 1:STN:280: DC%2BD1cngsFOmtQ%3D%3D 18793332 10.1111/j.1365-2796.2008.01981.x
6. F Gascon D De la Fuente J Puente J Lozano 2007 On macroeconomic characteristics of pharmaceutical generics and the potential for manufacturing and consumption under fuzzy conditions Artif Intell Med 41 223 235 10.1016/j.artmed.2007.07.001 http://www.drugs.com 17719212 10.1016/j.artmed. 2007.07.001 Cited March 2008 (Pubitemid 350018986)
7. PV Grootendorst LR Dolovich BJ O'Brien AM Holbrook AR Levy 2001 Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs CMAJ 165 8 1011 1019 1:STN:280:DC%2BD3MnkslWntw%3D%3D 11699696 16
8. C Huttin 2002 Experiences with reference pricing Int J Risk Saf Med 15 85 91
9. Karam R (2010) Survey report: prices of medicines in Lebanon. Health Action International Project on Medicine Prices, World Health Organization, Geneva. http://www.haiweb.org/medicineprices/surveys/200402LB/survey-report.pdf. Cited 9 May 2010
10. TH Lee 2004 "Me-too" products: friend or foe? N Engl J Med 350 211 212 10.1056/NEJMp038215 1:CAS:528:DC%2BD2cXkvVGhtA%3D%3D 14724297 10.1056/NEJMp038215 (Pubitemid 38067631)
11. BI Levy 2005 How to explain the differences between renin angiotensin system modulators Am J Hypertens 18 134S 141S 10.1016/j.amjhyper.2005.05.005 1:CAS:528:DC%2BD2MXhtFOjsL3E 16125050 10.1016/j.amjhyper.2005.05.005 (Pubitemid 41206570)
12. J Luno M Praga S de Vinuesa 2005 The reno-protective effect of the dual blockade of the renin angiotensin system (RAS) Curr Pharm Des 11 10 1291 3000 1:CAS:528:DC%2BD2MXivVCqtLY%3D 15853685 10.2174/1381612053507413 (Pubitemid 40458274)
13. J Mestre-Ferrandiz 2003 Reference prices and generic medicines: What can we expect? J Generic Med 1 31 38 10.1057/palgrave.jgm.4940015 10.1057/palgrave.jgm.4940015 (Pubitemid 46218663)
14. Ministry of Health (2005-2007) Drug price registry. www.mh.government.bg. Cited 2005, 2006, and 2007
15. S Morgan G Kenneth L Bassett J Wright R Evans M Barer P Caetano C Black 2005 "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada BMJ 331 8 815 816 10.1136/bmj.38582.703866.AE 16141448 10.1136/bmj.38582.703866.AE (Pubitemid 41442361)
16. M Mrazek 2002 Comparative approaches to pharmaceutical price regulation in the European Union Croat Med J 43 4 453 461 12187524
17. M Raizada A Ferreira 2007 ACE 2: a new target for cardiovascular disease therapeutics J Cardiovasc Pharmacol 50 2 112 119 10.1097/FJC.0b013e3180986219 1:CAS:528:DC%2BD2sXptFemsbw%3D 17703127 10.1097/FJC.0b013e3180986219 (Pubitemid 47267736)
18. Rossi S (ed) (2006) Australian medicines handbook 2006. Australian Medicines Handbook, Adelaide
19. Rossi S (ed) (2009) Australian medicines handbook 2008. Australian Medicines Handbook, Adelaide
20. Scott Morton FM (1999) Entry decisions in the generic pharmaceutical industry. The RAND J Econ 30(3) 421-440
21. S Simoens S de Coster 2006 Sustainable generic medicines market in Europe J Generic Med 3 4 257 268 10.1057/palgrave.jgm.4950040 10.1057/palgrave.jgm. 4940128 (Pubitemid 46218085)
22. TP Stossel 2008 The discovery of Statins Cell 6 134 903 905 10.1016/j.cell.2008.09.008 10.1016/j.cell.2008.09.008
23. PS Wang AR Patrick CR Dormuth J Avorn M Maclure CF Canning S Schneeweiss 2008 The impact of cost sharing on antidepressant use among older adults in British Columbia Psychiatr Serv 59 377 383 10.1176/appi.ps.59.4.377 18378836 10.1176/appi.ps.59.4.377
24. WHO (World Health Organisation) (2003) Introduction to drug utilization research. WHO, Geneva
25. WHO (World Health Organisation) (2007) The world medicines situation. (WHO/EDM/PAR/2004.5) Geneva, p 39
26. UDB Zaheer IMI Mohamed H Singh NI Bukahri A Creese 2007 Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia PLoS Med 4 3 e82 10.1371/journal.pmed.0040082.t00 10.1371/journal.pmed.0040082
27. National Economic research Associate (2009) Policy Relating to Generic Medicines in the OECD. http://ec.europa.eu/enterprise/pharmaceuticals/pharmacos/ docs/nerareport. (Accesed August 2009)